Search

Your search keyword '"Harcharik, Sara"' showing total 6 results
Start Over Author "Harcharik, Sara" Search Limiters Available in Library Collection
6 results on '"Harcharik, Sara"'

1. Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease

Author

Sivendran, Shanthi, Chang, Rui, Pham, Lisa, Phelps, Robert G., Harcharik, Sara T., Hall, Lawrence D., Bernardo, Sebastian G., Moskalenko, Marina M., Sivendran, Meera, Fu, Yichun, de Moll, Ellen H., Pan, Michael, Moon, Jee Young, Arora, Sonali, Cohain, Ariella, DiFeo, Analisa, Ferringer, Tammie C., Tismenetsky, Mikhail, Tsui, Cindy L., Friedlander, Philip A., Parides, Michael K., Banchereau, Jacques, Chaussabel, Damien, Lebwohl, Mark G., Wolchok, Jedd D., Bhardwaj, Nina, Burakoff, Steven J., Oh, William K., Palucka, Karolina, Merad, Miriam, Schadt, Eric E., and Saenger, Yvonne M.

Published
2014
Full Text
View/download PDF

3. Oncolytic virus therapy for cancer

Author

Kaufman, Howard, Goldufsky,Joe, Sivendran, Harcharik,Sara, Pan,Michael, Bernardo,Sebastian, Stern,Richard H, Friedlander,Philip, Ruby,Carl, and Saenger,Yvonne

Subjects
Oncolytic Virotherapy, viruses
Abstract

Joe Goldufsky,1 Shanthi Sivendran,3 Sara Harcharik,4 Michael Pan,4 Sebastian Bernardo,4 Richard H Stern,5 Philip Friedlander,4 Carl E Ruby,1,2 Yvonne Saenger,4 Howard L Kaufman1,2 Departments of 1Immunology & Microbiology and 2Surgery, Rush University Medical Center, Chicago IL, USA 3Hematology/Oncology Medical Specialists, Lancaster General Health, Lancaster, PA, USA, and Departments of 4Medical Oncology and 5Radiology, Tisch Cancer Institute, The Mount Sinai School of Medicine, New York, NY, USA Abstract: The use of oncolytic viruses to treat cancer is based on the selection of tropic tumor viruses or the generation of replication selective vectors that can either directly kill infected tumor cells or increase their susceptibility to cell death and apoptosis through additional exposure to radiation or chemotherapy. In addition, viral vectors can be modified to promote more potent tumor cell death, improve the toxicity profile, and/or generate host antitumor immunity. A variety of viruses have been developed as oncolytic therapeutics, including adenovirus, vaccinia virus, herpesvirus, coxsackie A virus, Newcastle disease virus, and reovirus. The clinical development of oncolytic viral therapy has accelerated in the last few years, with several vectors entering clinical trials for a variety of cancers. In this review, current strategies to optimize the therapeutic effectiveness and safety of the major oncolytic viruses are discussed, and a summary of current clinical trials is provided. Further investigation is needed to characterize better the clinical impact of oncolytic viruses, but there are increasing data demonstrating the potential promise of this approach for the treatment of human and animal cancers. Keywords: cancer, gene therapy, oncolytic therapy, virus, treatment

Published
2013

5. Oncolytic virus therapy for cancer.

Author

Goldufsky, Joe, Sivendran, Shanthi, Harcharik, Sara, Pan, Michael, Bernardo, Sebastian, Stern, Richard H., Friedlander, Philip, Ruby, Carl E., Saenger, Yvonne, and Kaufman, Howard L.

Published
2013
Full Text
View/download PDF

6. Steroid-sparing properties of emollients in dermatology.

Author

Harcharik S and Emer J

Subjects
Adrenal Cortex Hormones therapeutic use, Calcineurin Inhibitors therapeutic use, Ceramides therapeutic use, Dermatitis, Atopic drug therapy, Dimethylpolysiloxanes therapeutic use, Humans, Petrolatum therapeutic use, Emollients therapeutic use, Skin Diseases drug therapy
Abstract

Topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) are very effective treatments in inflammatory dermatoses, but carry risks with long-term use. TCS are associated with cutaneous atrophy and tachyphylaxis and TCIs can be irritating and contain a black box warning of an increased risk of cancers including lymphoma and non-melanomatous skin cancers. Nevertheless, they are appropriate treatments for inflammatory conditions such as psoriasis and atopic dermatitis (AD) and should be used more often with disease flares and less as maintenance therapy. Given the associated risks of long-term continuous use with these pharmacologic agents, alternatives are needed with similar anti-inflammatory and barrier repair properties that can be used indefinitely without risk. Some over-the-counter (OTC) ingredients such as colloidal oatmeal and petrolatum, as well as anti-inflammatory prescription moisturizers (medical device creams), have demonstrated efficacy with little complications in skin barrier repair and symptom relief in steroid-responsive conditions. With regimented application, these non-drug options are safe and effective and can limit the longterm continuous use of TCS or TCIs.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results